Features | Partner Sites | Information | LinkXpress
Sign In
AB Sciex
Bio-Rad Diabetes Division
RANDOX LABORATORIES

Expression of Antigen Evaluated for Prostate Cancer

By Labmedica International staff writers
Posted on 14 Feb 2012
The expression of the cancer/testis antigen, A-kinase anchor protein 4 (AKAP-4), has been evaluated in prostate cancer (PC) patients.

The exploitation tumor-associated antigens, not only for screening purposes, but also as targets for tumor immunotherapy underlines their relevance in oncology and is due to features frequently shared by molecular biomarkers and tumor antigens.

Scientists at Texas Technical University (Lubbock, TX, USA) analyzed normal prostate tissues, 15 patients with PC and the LnCAP PC cell line by immunohistochemistry. The immunogenicity of AKAP-4 was tested through indirect enzyme-linked immunosorbent assay (ELISA) on sera from cancer patients and healthy subjects. In vitro AKAP-4-specific cytotoxic lymphocytes were generated from peripheral blood mononuclear cells. Reverse transcriptase polymerase chain reaction (RT-PCR) was used to measure AKAP-4 messenger ribonucleic acid (mRNA) expression.

The AKAP-4 was shown both at the cytoplasmic and surface levels of the LnCAP PC cell line. AKAP-4 was also highly expressed in PC cells from patients. Specific anti-AKAP-4 circulating immunoglobulins were detected in AKAP-4 positive subjects. The use of recombinant AKAP-4-loaded autologous dendritic cells generated AKAP-4-specific and human leukocyte antigen-1 (HLA-I)-restricted cytotoxic T lymphocytes able to kill PC cells in vitro. Further characterization indicated a T-helper cell (Th-1) skewing in the cytokine secretion profile of these cells.

The indirect ELISA was performed using specific reagents from Pierce (Rockford, IL, USA) and the ELISA for T Cell Cytokine Expression used sandwich ELISA kits from U-CyTech (Utrecht, The Netherlands). The authors concluded that the aberrant expression of AKAP-4 in PC will potentially be developed as a biomarker in PC and is a potential target for immunotherapy. The study was published in the January 2012 issue of the journal the Prostate.

Related Links:

Texas Technical University
Pierce
U-CyTech



PURITAN MEDICAL
77 ELEKTRONIKA
DiagCor Bioscience
comments powered by Disqus
Sekisui Diagnostics

Channels

Clinical Chemistry

view channel
Image:  The Agilent 6890 GC with 5973 Mass Spectrometer and Tekmar Velocity XPT Purge & Trap (Photo courtesy of Gen Tech).

Low Levels of Prohormone Predicts Coronary Heart Disease

The adrenal sex hormone dehydroepiandrosterone (DHEA), which is present in serum mainly as the sulfate DHEA-S, is the most abundant steroid hormone in human blood and its levels decline dramatically with age.... Read more

Microbiology

view channel
Image: The causative parasite of Chagas disease Trypanosoma cruzi in a blood film (Photo courtesy of the CDC - US Centers for Disease Control and Prevention).

Undiagnosed Chagas Disease Emerging as Public Health Threat

Chagas disease or American trypanosomiasis is typically spread to people through the feces of blood-sucking triatomine bugs sometimes called kissing bugs because they feed on people's faces during the night.... Read more

Pathology

view channel
Image: The Isolation by Size of Epithelial Tumor cells (ISET) technology (Photo courtesy of Rarecells Diagnostics).

Circulating Tumor Cells Allow Early Diagnosis of Lung Cancer

Chronic obstructive pulmonary disease (COPD) is a risk factor for lung cancer and migration of circulating tumor cells (CTCs) into the blood stream is an early event that occurs during carcinogenesis.... Read more

Industry News

view channel

Oncology Companion Diagnostics Sector Grows to Over USD 1 Billion

The market for diagnostic test and pharmaceutical drug pairs for cancer treatment has grown significantly, according to the report “Companion Diagnostic Markets” from healthcare market research firm Kalorama Information (New York City, NY, USA). The global companion diagnostics (CDx) market is valued at about USD 1.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.